14
GeneThera Inc. “Safer Food Safe with Better Technology”

GeneThera, Inc. Corporate Summary

Embed Size (px)

DESCRIPTION

GeneThera, Inc.'s Corporate Summary

Citation preview

Page 1: GeneThera, Inc. Corporate Summary

GeneThera Inc.“Safer Food Safe with Better Technology”

GeneThera Inc.“Safer Food Safe with Better Technology”

Page 2: GeneThera, Inc. Corporate Summary

The CompanyThe CompanyGeneThera, Inc., an international biotechnology company that focuses on the “crossover disease” market, we develop molecular assays and therapeutics for the detection of food contaminating pathogens, veterinary diseases, and genetically modified organisms that inhabit farm animals that potentially can transfer to humans through the food supply.

GeneThera“Crossover Diseases”

Johne’sDisease

Mad CowDisease

Tuberculosis

Page 3: GeneThera, Inc. Corporate Summary

Corporate TeamCorporate Team

Dr. Tony Milici, Chairman and CEO, Dr. Antonio Milici founded GeneThera in 1999 and has served as its Chairman and CEO since inception. Prior to starting GeneThera, Dr. Milici was CEO and President of Genetrans, Inc., a genetic diagnostic company. Dr. Milici was also an assistant professor in the department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center. Dr. Milici’s educational background is as follows: in 1983 he was awarded/earned a Ph.D. (Experimental Hematology) University of Rome/Stanford University California, Rome, Italy/Stanford, California; in 1979 an M.D. (Medicine and Surgery) University of Rome, Rome, Italy; in 1973 a B.S. in Classic Literature/Art/Philosophy/Science), Classic Lyceum, Rome, Italy. Dr. Milici’s specialties include Molecular Biology, Biotechnology, Molecular Medicine, Gene Therapy, Molecular Oncology, and Molecular Diagnostics.

Tannya L. Irizarry has served as Chief Administrative Officer of GeneThera since 1999. Currently, she is acting as Chief Financial Officer. Ms. Irizarry has over eighteen years of experience in the medical and biotechnology industries. Ms. Irizarry worked at the University of Texas M.D. Anderson Cancer Center in the Neuro-Oncology Department and Office of Education; and at St. Joseph Hospital in the biotechnology division. Ms. Irizarry served as Vice President for Genetrans, Inc. from 1994 until 1998. 

Jose R. Sandoval has been consulting with GeneThera, Inc. since March of 2006 and has served as our Consulting Controller since May, 2006. Mr. Sandoval has seven years of experience in Accounting Management. Mr. Sandoval spent most of his years in the environmental industry as a Controller and Accounting Manager. Mr. Sandoval attended Adams State College in Alamosa, CO. He received his Bachelor of Science, Business Administration (B.S.B.A.) Degree in Accounting, with a minor in Finance.

James Huang, Consulting Scientist, brings over 15 years of industrial biotechnology experience. Mr. Huang is a molecular biologist with a focus on vaccine development. He has extensive experience in clinical trials and GNP production. He has a Ph.D. from North Carolina University, a MS from National Taiwan University and a BS from National Chung Hsing University.

Page 4: GeneThera, Inc. Corporate Summary

Target Market – Industry PainTarget Market – Industry Pain

Johne’s Disease

Johne's disease results from infection with bacteria called Mycobacterium paratuberculosis. This organism grows very slowly, causes a gradually worsening disease condition, and is highly resistant to the infected animal's immune defenses. Therefore, infected animals harbor the organism for years before they test positive or develop disease signs.

Drivers:

• Reduction in milk production up to 25%.

• Increased costs due to feeding inefficiency.

• High culling rate which increases costs.

• Johne’s affects trade and hinders exports.

• Additional costs involved to meet regulations and to mitigate disease.

• Studies are discovering a link between Johne’s and Crohn’s disease.

Johne’s disease has a world wide economic impact of over $5 billion and over $1.5 billion in the United States

Page 5: GeneThera, Inc. Corporate Summary

Johne’s Disease and Crohn’s DiseaseJohne’s Disease and Crohn’s DiseaseAn overwhelming number of studies point to a relation between Johne’s Disease and Crohn’s. 80% of the patients with Crohn’s are positive for Mycobacterium Paratubercolosis (MAP) infection when examined by intestinal biopsy.(Fouad A. K. El-Zaataria, Michael S. Osatob and David Y. Graham, a Inflammatory Bowel Disease Laboratory, Veterans Affairs Medical Center and Department of Medicine, Baylor College of Medicine, 2002 Holcombe Blvd, Rm 3A-320, Houston, TX 77030, USA)

Drinking milk from cows infected with Johne’s disease is how people are exposed to paratuberculosis infection.Milk is the "logical" focus of exposure because cows with Johne's disease secrete MAP abundantly in their milk. Milk studies done in Europe, among them a study from Switzerland in 2003, where 1,384 bulk milk samples from different regions were tested for M. paratuberculosis using DNA probe methods,show that 19.7 percent were positive for the bacteria. Intriguingly, the cows from Swiss farms were predominantly asymptomatic – they were apparently ill, but not producing the massive diarrhea that characterizes the latter stages of M. paratuberculosis infection.In 1984 Dr. Rodrick Chiodini,at Brown University demonstrated that m. paratuberculosis sheds its cell wall in humans, and takes a new form, called a spheroblast. In a landmark study, Dr. Chiodini cultured Mycobacteria from children infected with Crohn's.

Further establishing the causative link, M. paratuberculosis isolated from Crohn's patients was found to cause a similar disease when fed to farm animals.

Page 6: GeneThera, Inc. Corporate Summary

The total available market (TAM) consists of all sheep and cattle dairy head in the world as an aggregate, this total is in excess of 800 million heads.

The details as follows: – North America (41 million) which encompasses (USA,

Mexico, and Canada).– South America (45 million) which encompasses (Brazil and

Argentina).– Europe (95 million) which encompasses (Italy, UK,

France, Germany).– Asia (395 million) which encompasses (China, Australia,

India, and New Zealand).– Rest of World (ROW) which is 298 million.

0

100,000,000

200,000,000

300,000,000

400,000,000

Dairy Heads

NorthAmerica

SouthAmerica

Europe Asia ROW

Regions

Total Available Market (TAM)

Sheep

Cattle

Total Available Market (TAM)Total Available Market (TAM)

Page 7: GeneThera, Inc. Corporate Summary

Share of Available Market (SAM)Share of Available Market (SAM)

The TAM of the dairy head is enormous and we at GeneThera will discount the size due to many herds being in remote locations, infrastructure, and the demand for testing or managing herds is not uniform across all regions and farms. We will focus in on key developing countries with mid to large dairy farms. Based on our assumptions our SAM is valued at $5.7 billion.

020,000,00040,000,00060,000,00080,000,000

100,000,000

Dairy Heads

NorthAmerica

SouthAmerica

Europe Asia ROW

Regions

Share of Available Market (SAM)

Sheep

Cattle

Page 8: GeneThera, Inc. Corporate Summary

Share of Market (SOM)Share of Market (SOM)

After extensive surveys and in depth conversations with our partners, dairy farms, and government agencies we believe we will capture an extensive amount of market share initially and expect gradual growth as we continue in the years. – The remainder of our regions will grow according to

conservative projection (refer to revenue projections).

– Market share represents dairy head count, revenues recognized through products sales based on market penetration.

– Market projection does not include sales to milk distribution facilities, government agencies, beef cattle farms, academia, or research companies.

– Our SOM is valued at $605 million annually.

02,000,0004,000,0006,000,0008,000,000

10,000,00012,000,00014,000,000

Dairy Heads

NorthAmerica

SouthAmerica

Europe Asia ROW

Regions

Share of Market (SOM)

Sheep

Cattle

Page 9: GeneThera, Inc. Corporate Summary

The TechnologyThe TechnologyIntegrated Technology Platform

GeneThera’s animal disease assay development business is based on its Integrated Technology Platform (ITP) that combines a proprietary diagnostic solution called Gene Expression System (GES) with PURIVAX™, a highly sophisticated purification system that removes contaminating particles from biological fluids. The first part of this platform is the ongoing development of molecular diagnostic assay solutions using real time Fluorogenic Polymerase Chain Reaction (F-PCR)Integrated Automation System technology to detect the presence of infectious disease from the blood, feces and milk of live animals.

The second part of the ITP is the development of therapeutic vaccines using RNA interference technology. Interference RNA technology is a new technique that is based on the use of short RNA sequences complementary to a specific target gene. Once the RNA sequence binds to the gene, the gene is deactivated or “silenced” and no longer able to produce the specific protein. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations.

These facts distinguish the technology from any alternative testing and management methodology available today – all of which require the destruction of individual animals and even entire herds. Our testing and data analysis processes also allow us not only to separate infected from clean animals, but also to gain knowledge vital to development of preventative vaccines.

Page 10: GeneThera, Inc. Corporate Summary

The DifferentiationThe Differentiation

GeneThera’s proprietary technology is the only company at this time to create both a diagnostic and therapeutic that mitigates and controls specific “cross over diseases.”

• Increase milk productivity

- increases revenues and improves margins.

• Reduction in animal culling and feed costs.

• Reduction in costs associated with regulations and veterinarian expenses.

• Improve genetic integrity of the herds, thus better future productivity.

• Increase revenues by opening markets by increasing exports.

• Ability to transfer model into other animal “crossover diseases.”

We provide the following benefits to our markets

Page 11: GeneThera, Inc. Corporate Summary

Integrated Product Development Integrated Product Development

Herd Guard

TestHerdChec

k Therapy

HerdSafe

ManageHerdSoft

Page 12: GeneThera, Inc. Corporate Summary

HERDCHECK (Molecular Assays)HerdCheck is our diagnostic product.Samples are collected using a Field Collection System with includes specific collection tubes and ship to a GeneThera laboratory for processingThe major features of the testing system are:High throughput system Capable of more than 20,000 tests/month.Highly defined and structured testing system.Proprietary Real Time PCR technology

Page 13: GeneThera, Inc. Corporate Summary

HerdSafe ( Genetic Therapy)

HerdSafe is our therapeutic product. Heard safe combines an immunotherapy treatment (LIPOSTIM) and large-scale purification and recombinant based DNA vaccine using Adenovirus and AVV genetically engineered viruses. (PURIVAX)

LIPOSTIM™ is an immunotheraphy treatment is able to significantly enhance antimycobacterial innate immune response while simultaneously limiting tissue damage. Our proprietary technology has been tested in vitro on macrophages infected with mycobacterium paratubercolosis and shown to be highly effective in blocking the mycobacterial infection.

Page 14: GeneThera, Inc. Corporate Summary

HERDSOFTHerdSoft™ is our comprehensive Johne’s Disease management solution which is a web-based product connected to our data center. The management system will deliver results, collect data and incorporate environmental analysis to guide the client on therapy and management of their herd to controlJohne’s Disease in their facility.